Tocofersolan is a derivative of alpha tocopherol used to treat vitamin E deficiencies. D-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis.
- Mechanism
- Curator reviewed · 1 reference
Vitamin E is a major lipo-soluble antioxidant in humans. It acts as a free radical chain breaking molecule, halting the peroxidation of polyunsaturated fatty acids and it plays an important role in maintaining both the stability and integrity of cell membranes.
- Primary indication
- Tocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth (full term newborns) up to 18 years of age.Curator reviewed · 1 structured indication
- First approval
- Canada, 2001 · European Union, 2017
- Also known as
- (+)-.ALPHA.-TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE · D-.ALPHA.-TOCOPHEROL POLYETHYLENE GLYCOL 1000 SUCCINATE · Mono-[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanyl] succinate polyethylene glycol monoester · POLY(OXY-1,2-ETHANEDIYL), .ALPHA.-(4-((3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2-(4,8,12-TRIMETHYLTRIDECYL)-2H-1-BENZOPYRAN-6-YL)OXY)-1,4-DIOXOBUTYL-.OMEGA.-HYDROXY- · Tocophersolan
- Brand names
Resolves to
What you can answer from here — as of October 11, 2024
Which drugs share a target with Tocofersolan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account